Images List Premium Download Classic

Psychiatric

Psychiatric-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
5-ht3 receptor antagonists
September 14, 2017 - N°20170260201

Which are useful for the treatment of diseases treatable by inhibition of 5-ht3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and gi disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Methyl oxazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
September 14, 2017 - N°20170260177

The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Heteroaryl orexin receptor antagonists
Merck Sharp & Dohme Corp.
September 14, 2017 - N°20170260136

The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Transgenic mouse model for conditional fkbp51 expression and related methods
University Of South Florida
September 14, 2017 - N°20170258940

The subject invention pertains to transgenic non-human animals comprising a transgenic nucleotide sequence, integrated into the genome of the animals, comprising a nucleotide sequence encoding human fkbp51 operably linked to a tetracycline response element. In some embodiments, the transgenic animal comprises an additional transgenic nucleotide sequence, integrated into the genome of the animal, comprising a nucleotide sequence encoding a tetracycline ...
Ester of a phospholipid with conjugated linoleic acid for the treatment of psychiatric disorders with ...
Universita' Degli Studi Di Cagliari
September 14, 2017 - N°20170258924

An ester of a phospholipid with conjugated linoleic acid for use in the therapeutic treatment of or as a food supplement for psychiatric disorders with neuroinflammatory and neurodegenerative basis, such as depression and schizophrenia.
Method and system to predict response to treatments for mental disorders
Pathway Genomics Corporation
September 07, 2017 - N°20170253928

The present inventions relates to methods and assays to predict the response of an individual to psychiatric treatment and to a method to improve medical treatment of a disorder, which responsive to treatment with a psychiatric treatment.
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Systems level state characteristics in experimental treatment of disease
Prexton Therapeutics Sa
September 07, 2017 - N°20170251943

Methods and system for assessment of a state of the central nervous system (cns) of a subject and/or differentiation between states of the cns at a specific time point based on electrophysiological recordings of signals from at least two anatomical structures, wherein the signals are recorded from recording sites located in the anatomical structures, wherein the electrophysiological recordings comprise ...
Substituted 4-alkoxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the ...
Vanderbilt University
August 31, 2017 - N°20170247366

Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mglur5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended ...
Method of treating organophosphate intoxication
The Texas A&m University System
August 31, 2017 - N°20170246188

The present invention provides new compositions and methods for treating and/or reversing organophosphate intoxication, manifested by both cholinergic and non-cholinergic crisis, in a mammal resulting from exposure to organophosphate compounds. The neurosteroidal compounds of this invention are those having the general structural formula of pregnane, androstane, 19-norandrostanes, and norpregnane with further moieties as defined herein. These compounds include, but ...
Amphiphilic compounds with neuroprotective properties
Fyziologicky Ustav Av Cr, V.v.i.
August 24, 2017 - N°20170240588

Amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use in methods of treatment of neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of cns, neurodegenerative changes and disorders of cns, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, ...
N-substituted-5-substituted phthalamic acids as sortilin inhibitors
Fyziologicky Ustav Av Cr, V.v.i.
August 24, 2017 - N°20170239226

The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motoneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as alzheimer's disease and parkinson's disease.
(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2...
Bristol-myers Squibb Company
August 03, 2017 - N°20170216325

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system.
Treating various disorders using trkb agonists
Emory University
August 03, 2017 - N°20170216319

Novel compounds and methods for activating the trkb receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing four six-membered rings and a substituted or unsubstituted c5 or c6 heteroaryl or heterocycloalkyl ring and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods and compounds for the treatment of disorders ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Therapeutic isoxazole compounds
Dana-farber Cancer Institute, Inc.
July 20, 2017 - N°20170204111

Wherein a1, a2, a3, r1, x, y, and b have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase b (mao-b) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders ...
Imidazolyl kinase inhibitors and uses thereof
Dana-farber Cancer Institute, Inc.
July 20, 2017 - N°20170204082

The present disclosure provides imidazolyl compounds of formula (i) and methods of preparing the compounds. The provided compounds are able to bind protein kinases and may be useful in modulating (e. G., inhibiting) the activity of a protein kinase in a subject or cell and/or in treating or preventing a disease (e. G., proliferative disease, genetic disease, hematological disease, ...
Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders and inflammation, ...
Universitat Bern
July 13, 2017 - N°20170197952

The invention relates to a compound comprising the following general formula (1) and said compound for use as a medicament, in particular for use in the treatment psychiatric or neurological disorders and inflammation, in particular neuroinflammation: (formula 1) wherein each of r1, r2 and r3 are selected independently from each other from alkyl, alkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, or heteroaryl.
Enantiomers of 8-hydroxyquinoline derivatives and the synthesis thereof
Universitat Bern
July 13, 2017 - N°20170197936

The subject matter of the invention furthermore relates to a novel, stereoselective synthesis for the preparation of the novel enantiomer derivatives according to the invention. The novel medicinal and/or pharmaceutical compositions comprising these enantiomers are suitable for the treatment of the named diseases, and the enanatiomers are used for manufacture of these compositions. These applications for manufacture of the ...
Allosteric modulators of cb1 cannabinoid receptors
Northeastern University
July 13, 2017 - N°20170197918

The present invention relates to novel heterocyclic derivatives which are allosteric modulators of cannabinoid receptor 1 (cb1) and which are useful for the treatment or prevention of neurological and psychiatric disorders associated with endocannabinoid dysfunction and diseases in which the cb1 subtype of cannabinoid receptor is involved; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of ...
2-aryl-4-hydroxy-1,3-thiazole derivatives useful as trpm8-inhibitors in treatment of neuralgia, pain, copd and ...
Northeastern University
July 06, 2017 - N°20170190678

Said compounds are useful in the treatment of diseases associated with activity of trpm8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exacerbated respiratory disorders and urological disorders.
Method of treatment of schizophreniform disorder
Curemark, Llc
July 06, 2017 - N°20170189501

Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of ...
Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center
July 06, 2017 - N°20170189358

Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e. G., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic ...
Loading